: Sarepta stock plunges more than 50% after mixed results from drug study

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.